How long does a Zepbound approval last with Centene?

Initial approvals last 6 months, and renewals are granted in 6-month periods.

What does Centene require to renew Zepbound?

At least 5% weight loss from the starting weight, First renewal: member must have lost >=5% of baseline body weight AND show at least one of: AHI reduction from baseline, improvement in SASHB score, or improvement in sleep-related patient-reported outcomes (ESS, Calgary SAQLI, FOSQ, or PROMIS). Second and subsequent renewals: member must have lost weight and/or maintained weight loss AND show stabilization or improvement in AHI, SASHB, or sleep-related patient-reported outcomes. Maintenance dose must be >=10 mg once weekly after initial dose escalation. Continued enrollment in physician-directed weight loss program required. Step therapy (prior GLP-1 trial for T2DM comorbidity) is NOT re-verified at continuation. First reauthorization: 6 months; subsequent reauthorizations: 12 months, and staying on a maintenance dose of at least 10 mg.

What if my plan excludes weight loss medications?

Centene has separate Zepbound policies for osa, which are covered on some plan types and don't depend on the weight-loss benefit. Zepbound is also available for cash through LillyDirect.

How current is this information?

This page reflects Centene's written policy as of December 20, 2024, last verified against the source document on June 2, 2026.

Centene

Does Centene cover Zepbound?

Quick answer · Weight Loss

Centene does not cover it for weight loss on ACA Marketplace.

ACA Marketplace: Not covered. Use of Zepbound for the treatment of weight management is a benefit exclusion and will not be authorized.

Last verified June 2, 2026. Policy effective December 20, 2024. Source: CP.PMN.298.pdf. How we verify this data →

Check your card for your exact plan →

Zepbound for Weight Loss

What Centene requires, by plan type. Open this indication on its own page →

ACA Marketplace

Not covered

Use of Zepbound for the treatment of weight management is a benefit exclusion and will not be authorized.

Policy note: The policy explicitly states that use of Zepbound for weight management is a benefit exclusion and will not be authorized, for both initial approval and continued therapy. This applies to HIM/ICHRA and Medicaid lines of business.

Policy effective December 20, 2024 · verified June 2, 2026 · source: CP.PMN.298.pdf

Zepbound for Osa

What Centene requires, by plan type. Open this indication on its own page →

ACA Marketplace

Covered with requirements

What you need to qualify

Age 18 and older
BMI of 30 or higher
6 months of a documented diet and exercise program
Prior trial of 3 other GLP-1 medications (Ozempic, Rybelsus, Trulicity, and liraglutide (generic Victoza)) for at least 90 days
Diagnosed obstructive sleep apnea (AHI of 15 or higher), with a documented trial of PAP therapy

Qualification pathways

You can qualify through any one of these.

Initial Approval – OSA (without concurrent T2DM)

All of:

Diagnosis of moderate to severe OSA confirmed by polysomnography or home sleep apnea test within past 12 months with AHI >= 15 respiratory events per hour
Age >= 18 years
BMI >= 30 kg/m2
Member does not have central or mixed sleep apnea
Active enrollment in physician-directed weight loss program for at least 6 months involving reduced calorie diet, increased physical activity, and behavioral modification, with plan to continue enrollment while on Zepbound
Zepbound not prescribed concurrently with other tirzepatide-containing products or any other GLP-1 receptor agonist
Documentation of member's baseline body weight in kg
Dose does not exceed escalation schedule (2.5mg wk1-4, 5mg wk5-8, 7.5mg wk9-12, 10mg wk13-16, 12.5mg wk17-20, 15mg wk21-24) and quantity limit (1 pen/vial per week for single-dose or 1 vial/KwikPen every 4 weeks for multi-dose)

Plus any one of:

Member has continued symptoms of OSA despite adherence to PAP therapy (>=4 hours/night for >=70% of nights)
Member is not a candidate for PAP therapy (e.g., upper airway anatomic abnormalities)

Initial Approval – OSA with concurrent T2DM (Illinois HIM: step therapy waived as of 1/1/2026)

All of:

Diagnosis of moderate to severe OSA confirmed by polysomnography or home sleep apnea test within past 12 months with AHI >= 15 respiratory events per hour
Age >= 18 years
BMI >= 30 kg/m2
Member does not have central or mixed sleep apnea
Concurrent diagnosis of type 2 diabetes mellitus
Member has received optimal diabetic standard of care therapy as evidenced by a trial of >= 3 consecutive months each of ALL of: (1) Ozempic or Rybelsus, (2) Trulicity, and (3) liraglutide (generic Victoza), unless clinically significant adverse effects are experienced or all are contraindicated
If member is currently on a GLP-1 receptor agonist and requesting switch to Zepbound, medical justification supports necessity (intolerance due to common GI adverse effects is NOT acceptable justification)
Active enrollment in physician-directed weight loss program for at least 6 months involving reduced calorie diet, increased physical activity, and behavioral modification, with plan to continue enrollment while on Zepbound
Zepbound not prescribed concurrently with other tirzepatide-containing products or any other GLP-1 receptor agonist
Documentation of member's baseline body weight in kg
Dose does not exceed escalation schedule and quantity limit

Plus any one of:

Member has continued symptoms of OSA despite adherence to PAP therapy (>=4 hours/night for >=70% of nights)
Member is not a candidate for PAP therapy (e.g., upper airway anatomic abnormalities)

Documentation to bring

Polysomnography or home sleep apnea test result within the past 12 months confirming AHI >= 15 respiratory events per hour
Documentation confirming absence of central or mixed sleep apnea
Documentation of member's baseline body weight in kg
Documentation of active enrollment in physician-directed weight loss program for at least 6 months (reduced calorie diet, increased physical activity, behavioral modification)
Documentation of continued enrollment in physician-directed weight loss program while on Zepbound
Documentation of PAP therapy adherence failure (>=4 hours/night for >=70% of nights with continued OSA symptoms) OR documentation that member is not a candidate for PAP therapy
For members with concurrent T2DM: Documentation of >= 3 consecutive months trial of each of Ozempic/Rybelsus, Trulicity, and liraglutide (generic Victoza) unless clinically significant adverse effects or contraindication documented (note: Illinois HIM waived as of 1/1/2026)
For members currently on a GLP-1 switching to Zepbound: Medical justification for the switch (GI intolerance to GLP-1 class is not acceptable)

Quantity limits

2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg — Single-dose formulation: 4 pens or vials (1 per week); Multi-dose formulation: 1 vial or KwikPen every 4 weeks; Single-dose formulation: 12 pens or vials; Multi-dose formulation: 3 vials or KwikPens (84-day)

Approval and renewal

Initial approval: 6 months
Renewal: every 6 months
To renew, the plan looks for at least 5% weight loss from the starting weight, First renewal: member must have lost >=5% of baseline body weight AND show at least one of: AHI reduction from baseline, improvement in SASHB score, or improvement in sleep-related patient-reported outcomes (ESS, Calgary SAQLI, FOSQ, or PROMIS). Second and subsequent renewals: member must have lost weight and/or maintained weight loss AND show stabilization or improvement in AHI, SASHB, or sleep-related patient-reported outcomes. Maintenance dose must be >=10 mg once weekly after initial dose escalation. Continued enrollment in physician-directed weight loss program required. Step therapy (prior GLP-1 trial for T2DM comorbidity) is NOT re-verified at continuation. First reauthorization: 6 months; subsequent reauthorizations: 12 months, and staying on a maintenance dose of at least 10 mg. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Central or mixed sleep apnea
Concurrent use with other tirzepatide-containing products
Concurrent use with any other GLP-1 receptor agonist
Personal or family history of medullary thyroid carcinoma (MTC) — contraindication
Multiple endocrine neoplasia syndrome type 2 (MEN 2) — contraindication
Known serious hypersensitivity to tirzepatide or any excipients in Zepbound — contraindication

Exceptions

Illinois_HIM: Step therapy requirements (prior GLP-1 trials for T2DM comorbidity and PAP therapy trial) do not apply for Illinois HIM requests as of 1/1/2026 per IL HB 5395

Policy note: Policy applies to HIM/ICHRA and Medicaid lines of business. OSA must be moderate to severe (AHI >= 15). The prior GLP-1 step therapy requirement (Ozempic/Rybelsus, Trulicity, liraglutide) applies ONLY to members with concurrent T2DM. PAP therapy must have been attempted and failed (with adherence defined as >=4 hours/night >=70% of nights) or member must not be a candidate for PAP. Continuation requires maintenance dose >=10 mg weekly after dose escalation. First reauthorization approval: 6 months; subsequent reauthorizations: 12 months. Multi-dose vials and KwikPens are available in 10, 20, 30, 40, 50, 60 mg/2.4 mL concentrations corresponding to four doses per vial/pen.

Policy effective December 20, 2024 · verified June 2, 2026 · source: CP.PMN.298.pdf

Why Zepbound requests get denied by Centene

Based on what this policy asks for. Fix these before the first submission.

Your plan's benefit excludes weight loss medications. A prior authorization cannot override a benefit exclusion — ask about a formulary exception or a different covered pathway.
Wrong brand for the diagnosis. Zepbound and Mounjaro are the same molecule with different approved uses; a request for Zepbound under a diagnosis that matches Mounjaro is routinely denied.
BMI not documented in the chart notes (or documented without a baseline weight and date).
No documented diet and exercise program.
Required prior medication trials not documented.
Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

If weight loss isn't covered on your plan

Centene has separate Zepbound policies that don't depend on the weight loss benefit:

Osa — covered on ACA Marketplace.

Zepbound is also sold directly by Eli Lilly without insurance through LillyDirect.

Frequently asked questions

Does Centene cover Zepbound?: Centene does not cover it for weight loss on ACA Marketplace.
How long does a Zepbound approval last with Centene?: Initial approvals last 6 months, and renewals are granted in 6-month periods.
What does Centene require to renew Zepbound?: At least 5% weight loss from the starting weight, First renewal: member must have lost >=5% of baseline body weight AND show at least one of: AHI reduction from baseline, improvement in SASHB score, or improvement in sleep-related patient-reported outcomes (ESS, Calgary SAQLI, FOSQ, or PROMIS). Second and subsequent renewals: member must have lost weight and/or maintained weight loss AND show stabilization or improvement in AHI, SASHB, or sleep-related patient-reported outcomes. Maintenance dose must be >=10 mg once weekly after initial dose escalation. Continued enrollment in physician-directed weight loss program required. Step therapy (prior GLP-1 trial for T2DM comorbidity) is NOT re-verified at continuation. First reauthorization: 6 months; subsequent reauthorizations: 12 months, and staying on a maintenance dose of at least 10 mg.
What if my plan excludes weight loss medications?: Centene has separate Zepbound policies for osa, which are covered on some plan types and don't depend on the weight-loss benefit. Zepbound is also available for cash through LillyDirect.
How current is this information?: This page reflects Centene's written policy as of December 20, 2024, last verified against the source document on June 2, 2026.

Other medications under Centene

Zepbound coverage under other plans

All insurance plans · All medications

This page summarizes Centene's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.